William G. Nelson, MD, Ph.D.
Dr. Nelson, a trained genitourinary medical oncologist, is a recognized leader in cancer research. Since 2008 he serves as the Marion I. Knott Director of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) and the Department of Oncology the Johns Hopkins University School of Medicine. His research laboratory, focused on prostate cancer, discovered one of the first epigenetically-silenced human cancer genes which became the basis for assays marketed as adjunct cancer diagnostic tests by MDxHealth (MDXH; Brussels).
Dr. Nelson has authored more than 250 published works, garnered nearly 30,000 citations, been granted 10 patents, and earned several prizes and honors. He serves on the Board of the V Foundation, as a Scientific Co-Chair for Stand Up to Cancer, and on the Scientific Advisory Board for the Prostate Cancer Foundation. He is also the Executive Editor of Cancer Today. He has been a Member of the Cancer Scientific Advisory Council for AbbVie, Inc. (ABBV; NYSE) and the Scientific Advisory Board for ProQuest Investments, Inc. He serves as an ad hoc consultant for GlaxoSmithKline, Inc. (GSK; NYSE), Merck and Co. (MRK; NYSE), and Celgene (CELG; NASDAQ) and a Co-Founder and Medic al Advisory Board Member for Digital Harmonics.
Dr. Nelson completed his internal medicine residency and medical oncology fellowship training at the Johns Hopkins Hospital where he became Professor of Oncology, Urology, Pathology, Pharmacology, Medicine, Radiation Oncology, and Environmental Health Sciences (1992). Dr. Nelson earned a B.A. in Chemistry at Yale University in 1980, and both an M.D. and a Ph.D. in Pharmacology in from Johns Hopkins in 1987.